Pharmacodynamics, Receptor Interactions, and Drug Interactions – Comprehensive Notes
Pharmacodynamics and Drug-Receptor Interactions
Focus: pharmacodynamics studies the relationship between drug concentration and drug effect, including how drugs interact with receptors to produce effects, and how factors like efficacy, potency, and toxicity arise.
Key ideas throughout today:
Drugs act at receptors to produce effects; occupancy of receptors is a prerequisite for effect.
Agonists activate receptors; antagonists block receptors; partial agonists activate but produce submaximal responses.
Affinity and intrinsic activity determine potency and efficacy.
Different dose–response relationships illustrate maximum efficacy and potency among drugs.
Interpatient variability, pharmacogenomics, and drug interactions influence response, safety, and dosing.
Special populations (pregnancy, pediatrics, geriatrics) alter pharmacodynamics and require adjustments.
Receptor Interactions and Core Concepts
Receptor occupancy: the basic idea that as drug concentration increases, more receptor sites are occupied/activated, driving the drug response.
Simple occupancy theory (conceptual):
As drug concentration increases, more receptor sites are filled, leading to a greater response.
This theory does not fully explain maximum efficacy or potency; intrinsic activity is needed for that.
Intrinsic activity: the ability of a bound drug to activate the receptor and produce a response.
High intrinsic activity → high maximal efficacy.
Low intrinsic activity → limited or inconsistent effect.
Partial agonist: binds and activates but produces submaximal effect even at full receptor occupancy (e.g., buprenorphine / Suboxone). It can act as an agonist or antagonist depending on the context (e.g., in the presence of full agonists).
Affinity: the strength of attraction between drug and receptor; determines potency (how much drug is needed to achieve effect).
High affinity → lower needed dose to achieve effect; may stay bound longer.
Low affinity → higher dose needed; may not stay bound long enough.
Example context: naloxone (antagonist) has high affinity for opioid receptors and can displace fentanyl, reversing effects.
Agonists vs antagonists (with examples):
Agonist: activates receptor and mimics endogenous substances (e.g., methadone, fentanyl, oxycodone). They have high affinity and high intrinsic activity.
Antagonist: binds receptor but does not activate it; blocks receptor activation by endogenous ligands or agonists (e.g., naloxone, naltrexone). They have high affinity but low intrinsic activity.
Partial agonist: intermediate activity; can act as antagonist in the presence of a full agonist (e.g., buprenorphine). Also typically high affinity with lower intrinsic activity.
Endogenous ligands: natural body compounds (e.g., endogenous opioids) that activate receptors; many therapeutic drugs are exogenous agonists/antagonists.
Reversibility of receptor binding: most drug–receptor interactions are reversible; binding is an equilibrium process. Naloxone can outcompete fentanyl due to higher affinity, allowing reversal of overdose.
Graphical perspective (dose–response curve): the same drug can reach 100% efficacy at different doses; potency is about the dose required to achieve a given effect, while efficacy is about the maximum achievable effect.
Agonists, Antagonists, and Partial Agonists (Visual Concept)
Agonist: fits receptor like endogenous ligand; high intrinsic activity; activates receptor.
Antagonist: binds receptor but does not initiate a response; blocks active site or changes receptor shape to prevent endogenous agonist binding.
Partial agonist: binds and partially activates receptor; may have dual roles (agonist or antagonist) depending on other drugs present.
Example classes and scenarios:
Beta-blockers: antagonize beta receptors to treat hypertension by blocking endogenous catecholamines.
Beta-agonists (e.g., albuterol): activate beta receptors to dilate airways.
Buprenorphine: partial agonist at mu-opioid receptor; high affinity with lower intrinsic activity; can block full agonists in opioid use disorder treatment.
Naloxone: antagonist with high affinity; used to reverse opioid overdose by displacing agonists from receptors.
Practical implications:
Availability of an antagonist with higher affinity than an agonist enables reversal or blockade of drug effects (e.g., opioid overdose).
Partial agonists can stabilize receptor activity and may serve dual roles depending on the presence of other opioids.
Dose–Response Curves: Efficacy vs Potency
Dose–response curves show drug dose (x-axis) vs percent of maximum effect (y-axis).
Key terms:
Efficacy (maximal effect): the ceiling of a drug’s effect regardless of dose; some drugs achieve 100% pain relief, others do not (e.g., aspirin may not achieve 100% pain relief).
Potency: the amount of drug needed to produce a given effect; more potent drugs require a smaller dose to reach a given effect.
Example curves (drugs treating pain):
Hydromorphone reaches 100% effect at a lower dose than morphine, which is lower than codeine (hydromorphone > morphine > codeine in potency).
Aspirin often does not reach 100% pain relief, indicating lower maximal efficacy for that endpoint compared to strong opioids.
Therapeutic window and therapeutic index:
Therapeutic window (or therapeutic index) is the range between minimum effective dose and minimum toxic dose.
A drug’s therapeutic window should be large and contained within safe dosing; the corresponding TI is often expressed as a ratio, TD50/ED50, though the transcript emphasizes the window concept.
Conceptual representation: as dose increases from left to right, you pass through efficacy, then toxicity if dose is too high.
Interpatient variability in pharmacodynamics:
Even with the same dose, patients may respond differently due to receptor density/sensitivity, pharmacogenomics, medication interactions, and comorbidities.
Genetic factors can lead to rapid or slow metabolism, receptor polymorphisms, and altered receptor sensitivity.
Tolerance and its implications:
Tolerance: diminished response to a drug with continued use, shifting the therapeutic window to the right (requiring higher dose for same effect).
Tolerance does not equate to addiction; use disorder involves psychological components in addition to pharmacodynamics.
Interpatient variability: other factors affect response
Other medications, concurrent conditions, hormonal differences (gender effects), and genetic polymorphisms influence receptor density/sensitivity and metabolism.
Pharmacokinetic/Pharmacodynamic Interactions (Red Flags & Mechanisms)
Two broad categories of drug interactions:
Pharmacokinetic interactions: affect drug levels by altering absorption, distribution, metabolism, or excretion (ADME).
Pharmacodynamic interactions: involve additive, synergistic, or antagonistic effects at or between receptors.
Pharmacokinetic interaction concepts:
p-glycoprotein (P-gp) effectors:
P-gp inducers increase transporter activity, reducing absorption and increasing elimination of certain drugs.
P-gp inhibitors decrease transporter activity, increasing absorption and decreasing elimination.
Cytochrome P450 (CYP) enzymes, especially CYP3A4 (major site of drug metabolism):
Inducers increase enzyme levels → faster drug metabolism → lower drug levels.
Inhibitors decrease enzyme activity → slower metabolism → higher drug levels.
A drug can be a substrate of a CYP enzyme (metabolized by that enzyme).
Grapefruit juice is a classic CYP3A4 inhibitor and can raise levels of drugs metabolized by CYP3A4 (e.g., tacrolimus).
Rifampin is a CYP3A4 inducer and can lower levels of drugs metabolized by CYP3A4 (e.g., tacrolimus)
Management may involve dose adjustments and therapeutic drug monitoring.
Example interaction narratives:
Tacrolimus + Grapefruit → higher tacrolimus levels due to CYP3A4 inhibition by grapefruit.
Tacrolimus + Rifampin → lower tacrolimus levels due to CYP3A4 induction by rifampin; may require dose increase and monitoring.
Warfarin + Bactrim (trimethoprim-sulfamethoxazole) interaction:
Bactrim inhibits CYP2C9; warfarin is a substrate of CYP2C9. Inhibition raises warfarin levels, increasing bleeding risk.
Important to distinguish substrates vs inducers vs inhibitors:
Substrate: drug is metabolized by the enzyme.
Inducer: drug increases enzyme levels, affecting metabolism of substrates.
Inhibitor: drug decreases enzyme activity, increasing substrate levels.
Pharmacodynamic interactions:
Drugs can compete for the same receptor (e.g., beta-blockers vs beta-agonists) leading to attenuated effects.
Synergy (additive effects) can be beneficial when two drugs work via different receptors/mechanisms to achieve a greater-than-additive effect (e.g., multi-drug regimens for hypertension using two drugs with different mechanisms).
Physiologic antagonism occurs when two drugs act on different receptors with opposing physiologic effects (e.g., epinephrine vs a drug that lowers blood pressure). Generally undesirable when opposing effects reduce the desired outcome.
Examples of synergy and antagonism in practice will be covered with antihypertensives and other common drug classes.
Absorption, Administration, and Food Interactions
Absorption is influenced by GI tract conditions and pH; some drugs must be taken with food to optimize absorption, others on an empty stomach.
With food vs without food:
With food: administer within 15 minutes of a meal; can improve absorption for certain drugs.
Without food: administer at least 1 hour before or 2 hours after a meal.
If a med is listed as “regardless of food,” it may be absorbed similarly with or without meals, but clinicians often standardize administration for adherence.
Take-with-water considerations:
Some drugs require a full glass of water to ensure proper dissolution and transit through the GI tract; others are unaffected.
Water volume and pH generally do not drastically alter many medications, but dissolution can matter for tablets or suspensions.
Food-specific notes:
Some antifungals (e.g., posaconazole) require acidic environments or specific foods (e.g., certain beverages) to optimize absorption.
Grapefruit should be avoided with many drugs due to CYP3A4 inhibition.
Practical example of timing and administration:
A drug may be dosed q12h (every 12 hours) to optimize adherence vs q8h due to practical considerations (home visits, caregiver burden).
Adverse Effects, Side Effects, and Black Box Warnings
Side effect vs adverse effect vs toxicity:
Side effect: nearly unavoidable secondary effect at therapeutic levels; can be unpredictable; often anticipated and discussed with patients.
Adverse effect: any undesired, harmful effect related to drug use; may require monitoring or intervention.
Toxicity: adverse effect at levels above the therapeutic range; can be life-threatening (e.g., severe hypoglycemia from excessive insulin).
Allergic reactions:
True allergic reactions are immune-mediated; less than 10% of reactions are true allergies.
Many reported “allergies” (e.g., constipation) are not true allergies; they are side effects or intolerances.
Black box warnings:
FDA-m mandated warnings highlighting serious or life-threatening risks; patients should know these for any medication with a black box warning.
Example: Accutane (isotretinoin) has a black box warning due to risk of fetal harm; contraindicated in pregnancy.
Counseling considerations:
Prepare patients for common side effects (e.g., diarrhea with amoxicillin-clavulanate) and advise on what to monitor.
Emphasize the difference between side effects and true allergies; document accurately.
When adverse events occur during hospital stays, they must be managed promptly using the five rights of drug administration, assessment, and monitoring.
Special Populations and Clinical Considerations
Pregnancy and lactation:
Nearly all drugs cross the placenta; risk vs benefit must be weighed.
Teratogenicity definition: a drug with a rate of at least 1% causing fetal structural abnormalities; about 1–3% of drugs are teratogenic.
FDA pregnancy labeling categories (legacy): A, B, C, D, X (historic system retaining some use).
Category A: controlled studies show no risk to fetus (essentially none in practice).
Category B: no demonstrated risk in humans; risk in animals, but not in humans.
Category C: no adequate human data; risk vs benefit considered.
Category D: evidence of human fetal risk; benefits may outweigh risk in serious situations.
Category X: contraindicated in pregnancy.
Since 2014, FDA labeling has evolved; many products still show A–D–X due to legacy practices.
Breastfeeding: nearly all drugs enter breast milk; levels are often low, but minimize exposure when possible; consider timing (post-breastfeeding dosing) and prefer drugs with less transfer.
Pediatrics:
Pediatric pharmacokinetics (ADME) vary by age; dosing often weight-based or body surface area-based.
Max adult dose is generally not exceeded in pediatrics; pediatric max doses are typically equal to or lower than adult max doses.
Geriatrics:
Aging affects absorption, distribution, metabolism, and excretion.
Volume of distribution may change due to body composition (increased fat, decreased water).
Protein binding can decline (lower albumin), affecting free drug levels.
Phase I metabolism tends to decrease; phase II metabolism may be preserved.
Renal function declines with age, impacting excretion and potential accumulation/toxicity.
Practical implications:
Monitor organ function and adjust doses in older adults.
Consider pharmacogenomics and potential drug–drug interactions, especially in patients on multiple meds.
Practical Scenarios and Exam Preparation
Exam logistics and preparation (as discussed in the session):
Expect a med math or pharmacology-focused quiz; practice problems ahead of time.
Questions may specify dose vs. time (dose vs. day) – read carefully.
Headers and unit awareness (liters vs milliliters) are important; units matter in calculations.
The pharmacodynamics focus today sets up pain management topics next:
Monday: migraines and related pain management concepts.
Thursday: med math quiz only; no class afterward.
TA resources and practice:
TAs are available via email; practice problems provided to build familiarity with question formats.
Examples and clinical reasoning cues to remember:
Naloxone vs fentanyl: high affinity reversal mechanism.
Buprenorphine in opioid use disorder: partial agonist with high affinity; can block other opioids.
Beta blockers vs beta agonists: opposing actions on the same receptor family.
Synergy in hypertension management: combining two drugs with different mechanisms for additive effects.
Physiologic antagonism: drugs with opposite physiologic effects at different receptors can reduce effectiveness when used together.
Quick recap of rounding and dose adjustments (conceptual):
Conventional rounding rules: values at 0.5 and above round up; below 0.5 round down.
Drops and discrete dosing: in drop-dose calculations, you cannot administer partial drops; round to a whole number of drops; the exact rounding approach may differ by protocol; always confirm the rounding convention used in your setting.
Summary of Key Formulas and Concepts (LaTeX)
Fractional receptor occupancy (conceptual):
Dose–response (basic pharmacodynamic model):
Therapeutic window and risk framing:
Therapeutic window (conceptual):
Therapeutic index (classic ratio):
Free (unbound) drug concept (impact of protein binding):
Reversal and affinity narrative (qualitative)
Pharmacokinetic interaction principles (definitions):
Substrate: drug metabolized by enzyme
Inducer: increases enzyme levels
Inhibitor: decreases enzyme activity
Ethical, Philosophical, and Practical Implications
The clinician must balance benefit and risk, especially in pregnancy, pediatrics, and geriatrics.
Understanding pharmacogenomics can improve safety and efficacy but is limited by cost/access; personalized medicine may not be feasible for all patients.
Clear patient communication about side effects, potential toxicities, and why certain medications are chosen over others is essential for adherence and safety.
Recognizing that tolerance and use disorders are distinct phenomena is critical to avoid conflating physical dependence with addiction.
Medication safety requires awareness of drug–drug, drug–food, and drug–disease interactions to prevent adverse outcomes and optimize therapeutic effects.
Quick References for Review
In overdose management: high-affinity antagonists can outcompete potent agonists at receptor sites (e.g., naloxone vs fentanyl).
In pain management, stronger opioids can achieve 100% efficacy at lower doses compared with weaker agents; consider potency and side-effect profiles when choosing therapy.
Pharmacokinetic interactions (CYP3A4, P-glycoprotein) are common and require monitoring (therapeutic drug monitoring where appropriate).
Special populations require tailored dosing strategies and heightened monitoring for adverse effects and toxicity.